Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Dieckmann

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
Advances in Simulation (London, England)|May 4, 2025
AI and inclusion in simulation education and leadership: a global cross-sectional evaluation of diversityJoana Berger-Estilita, Mia Gisselbaek, Arnout Devos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study GroupPeter Albers, Roswitha Siener, Susanne Krege, et al.
Clinical Genitourinary Cancer|October 11, 2021
A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor DiagnosisJin Piao, John T Lafin, Cinzia G Scarpini, et al.
Molecular Oncology|September 10, 2013
Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principleAd J M Gillis, Martin A Rijlaarsdam, Ronak Eini, et al.
Oncology Reports|May 3, 2014
German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practiceFriedemann Zengerling, Michael Hartmann, Axel Heidenreich, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohortAndreas Hiester, Anna Fingerhut, Günter Niegisch, et al.
Cancer|September 30, 2021
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative studyMarcus Ulrich Hentrich, Mark Bower, Gedske Daugaard, et al.
Cells|December 19, 2019
Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived DataJoão Lobo, Ad J M Gillis, Annette van den Berg, et al.
The American Journal of Surgical Pathology|February 22, 2026
International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting SurveyFelix Bremmer, Maurizio Colecchia, Katrina Collins, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
Advances in Simulation (London, England)|May 4, 2025
AI and inclusion in simulation education and leadership: a global cross-sectional evaluation of diversityJoana Berger-Estilita, Mia Gisselbaek, Arnout Devos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study GroupPeter Albers, Roswitha Siener, Susanne Krege, et al.
Clinical Genitourinary Cancer|October 11, 2021
A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor DiagnosisJin Piao, John T Lafin, Cinzia G Scarpini, et al.
Molecular Oncology|September 10, 2013
Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principleAd J M Gillis, Martin A Rijlaarsdam, Ronak Eini, et al.
Oncology Reports|May 3, 2014
German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practiceFriedemann Zengerling, Michael Hartmann, Axel Heidenreich, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohortAndreas Hiester, Anna Fingerhut, Günter Niegisch, et al.
Cancer|September 30, 2021
Outcomes of men with HIV and germ cell cancer: Results from an international collaborative studyMarcus Ulrich Hentrich, Mark Bower, Gedske Daugaard, et al.
Cells|December 19, 2019
Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived DataJoão Lobo, Ad J M Gillis, Annette van den Berg, et al.
The American Journal of Surgical Pathology|February 22, 2026
International Society of Urological Pathology (ISUP) Consensus Conference on Precursor Lesions: Working Group 4 Precursor Lesions of Testis Results of a Premeeting SurveyFelix Bremmer, Maurizio Colecchia, Katrina Collins, et al.
British Journal of Cancer|June 2, 2026
Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors studyMichal Mego, Edgar Israelyan, Robert J Hamilton, et al.
Pageof 23